NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

What it appears LP could, would and/or should know.

1. Shipping records of dose initiation (timing) regarding placebos that evented who chose to crossover. Maybe when new doses went unused for 36 months. Whether the UCLA slide from December 15, 2016 really meant all placebo had PFS evented. Why LL chose to speak then and who her targeted audience was.

2. Reason for the screening halt. Complete reason it was lifted. (Aka: full backstory)

3. Probably more frequently updated on OS eventing then yearly, because at one time back in 2017, Les gave me the impression he was updated far more frequently.

4. Blinded immune responses of patients.

5. Actual current status of LTFU and where they fall on the curve.

6. Enough or not enough information to still believe and state on June 3, 2018 that DCVax-L could become the frontline therapy for GBM.

7. What is truly the guiding principle for moving towards unblinding.

8. What is the current price NWBO thinks DCVax-L should be worth.

9. What capacity Cognate currently has to produce enough DCVax-L to meet expected demand in the United states.

10. Expected date for Advent to be prepared for commercial production.

11. Why she provided a loan that comes due in August.

12. The likelihood of meeting NICE timeline.

13. The likelihood and possible expected date for filing for marketing authorization in various countries/unions.

14. Whether or not efficacy IAs have been performed, and if they were performed, what their basic results/recommendations were.

15. Why they voluntarily halted enrolling in Germany around the same time as the screening halt.

16. Current rate of eventing, and how many surviving.

17. Why she believes the tail (of the KM survival curve) could get thicker when her own 69 investigators state there is no meaningful difference in survival based upon the year one was enrolled -- in an eleven year old trial.

18. Whether and to what degree manufacturing optimizations were made during the trial.

19. Why there is a randomization imbalance.

20. Lot's more.